- The Federal Office of Public Health (FOPH) announced at the end of February (see press release dated 26 February 2025) that financial support for the SwissPedDose database for paediatric medicinal products (based on Article 67a of the Therapeutic Products Act) will be discontinued after eight years at the end of the year 2025 for cost-saving reasons.
- The SwissPedDose association (swisspeddose.ch) is a forum in which expert knowledge from paediatric clinics throughout Switzerland is continuously brought together, compared with current scientific literature and harmonised to produce uniform dosage recommendations.
- The expert consensus and harmonisation lead to trust on the part of the users because the same recommendations apply throughout Switzerland and their origin is transparent.
- The current over 700 national dosage recommendations for 230 active substances for children can be accessed by all healthcare professionals free of charge at https://db.swisspeddose.ch at any time until the end of the year 2025.
- As before, an XML file with the current data set is available on request from SwissPedDose (or, as of the end of 2025, on request from the FOPH).
- SwissPedDose enables that the dosage recommendations in this database (https://db.swisspeddose.ch/) will be continuously available to all healthcare professionals also from 2026.
- SwissPedDose will operate its own database from 2026, keeping it continuously up to date and developing it at a minimal level.
- This database with dosage recommendations has the potential to essentially contribute to drug safety in children in the future, as it already does today.
- SwissPedPose is doing everything to make this happen and is looking for and evaluating funding opportunities.
13.05.2025
Interview with Prof. Christoph Berger about paediatric drug dosing and SwissPedDose
07.03.2025